Johnson & Johnson (JNJ) FY2026 Q2 P&L / Income Statement

Johnson & Johnson (JNJ) FY2026 Q2 P&L / Income Statement

Income statement for 2026-03-30 through 2026-06-28. View: Segments by Geographical. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Sales to customers (Note 9)

25,310,000,000 US dollars

Cost of products sold

8,051,000,000 US dollars

Gross profit

17,259,000,000 US dollars

Operating expenses (calculated)

10,119,000,000 US dollars

Operating profit (calculated)

7,140,000,000 US dollars

Other income (expense), net (calculated)

negative 393,000,000 US dollars

Earnings before provision for taxes on income

6,747,000,000 US dollars

Provision for taxes on income (Note 5)

1,213,000,000 US dollars

Net earnings

5,534,000,000 US dollars

Innovative Medicine - UNITED STATES

9,979,000,000 US dollars

Innovative Medicine - International

6,405,000,000 US dollars

MedTech - UNITED STATES

4,554,000,000 US dollars

MedTech - International

4,372,000,000 US dollars

Research and development expense

3,653,000,000 US dollars

Restructuring (Note 12)

34,000,000 US dollars

Selling, marketing and administrative expenses

6,432,000,000 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.